Vertex Pharmaceuticals Incorporated Stock News

All the elements are in place for a rebound.

Scout Investments Inc. raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 50.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 246,373 shares of the pharmaceutical companys stock after purchasing an additional 82,519 shares during the quarter. Scout Investments Inc.s []

Altfest L J & Co. Inc. increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 65.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,961 shares of the pharmaceutical companys stock after buying an additional 1,170 shares during the []

Biotechnology company Vertex Pharmaceuticals (NASDAQ: VRTX) has reported higher earnings and revenues for the third quarter of 2021. The bottom line also exceeded Wall Streets projection amid a 29% growth [] The post Vertex Pharma (VRTX) expands cystic fibrosis pipeline; raises FY21 outlook first appeared on AlphaStreet .

CRISPR's Life-Saving Technology Has Massive Potential

Wesbanco Bank Inc. bought a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 6,065 shares of the pharmaceutical companys stock, valued at approximately $1,100,000. Several other hedge funds and other institutional investors also recently made changes []

McElhenny Sheffield Capital Management LLC bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 2,594 shares of the pharmaceutical companys stock, valued at approximately $471,000. Several other hedge funds and other institutional investors have []

BMO Capital Markets began coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research report sent to investors on Thursday morning, Price Targets.com reports. The firm issued a market perform rating and a $202.00 price objective on the pharmaceutical companys stock. Several other equities research analysts also recently issued reports on VRTX. Royal Bank of []

Piper Sandler lowered shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from an overweight rating to a neutral rating in a report published on Thursday morning, Price Targets.com reports. The brokerage currently has $218.00 target price on the pharmaceutical companys stock, down from their previous target price of $323.00. VRTX has been the subject of several other research []

Equities research analysts expect that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will post earnings of $3.32 per share for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Vertex Pharmaceuticals earnings. The highest EPS estimate is $3.49 and the lowest is $3.10. Vertex Pharmaceuticals posted earnings per share of $2.51 in the same []

The companies are collaborating on a potential blockbuster.

The companies are collaborating on a potential blockbuster.

Over the past 3 months, 5 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ: VRTX ) stock. These analysts

BMO Capital Markets initiated coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research report report published on Thursday, Price Targets.com reports. The firm issued a market perform rating and a $202.00 price target on the pharmaceutical companys stock. A number of other equities research analysts also recently weighed in on VRTX. SVB Leerink boosted []

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Spanish government has approved terms for the national reimbursement of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) for eligible patients. The agreement covers people with CF ages 12 years and older who have at least one copy of the F508del mutation, regardless of the other mutation type in the CFTR gene. KAFTRIO®